Literature DB >> 8418186

Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages.

T B McNeely1, J D Coonrod.   

Abstract

Surfactant protein A (SP-A) is a glycosylated apoprotein that may facilitate bacterial phagocytosis and contribute to early bacterial clearance in the lung. The effect of SP-A on attachment (or ingestion) of Staphylococcus aureus and type 25 pneumococci to rabbit alveolar macrophages and human monocyte-derived macrophages was studied. SP-A bound to S. aureus and type 25 pneumococci in a calcium-dependent manner. Bacteria-associated SP-A significantly increased attachment of S. aureus, but not pneumococci, to macrophages. Increased association of SP-A-coated S. aureus with macrophages appeared to consist mainly of attachment without ingestion, as determined by bactericidal tests and release of tritiated bacterial digestion products from macrophages. Preincubation of macrophages with SP-A did not increase attachment or ingestion of S. aureus or type 25 pneumococci, with or without the addition of immune opsonins. SP-A acts as a ligand to facilitate attachment of S. aureus to macrophages but has no effect on S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418186     DOI: 10.1093/infdis/167.1.91

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

Review 1.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite.

Authors:  J Hickman-Davis; J Gibbs-Erwin; J R Lindsey; S Matalon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  Recognition of bacterial surface polysaccharides by lectins of the innate immune system and its contribution to defense against infection: the case of pulmonary pathogens.

Authors:  Hany Sahly; Yona Keisari; Erika Crouch; Nathan Sharon; Itzhak Ofek
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

4.  Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa.

Authors:  S Jain-Vora; A M LeVine; Z Chroneos; G F Ross; W M Hull; J A Whitsett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 5.  The role of surfactant-associated protein A in pulmonary host defense.

Authors:  V L Shepherd; J P Lopez
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

6.  Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells.

Authors:  S Schelenz; R Malhotra; R B Sim; U Holmskov; G J Bancroft
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Mitogen-activated protein kinases and NFkappaB are involved in SP-A-enhanced responses of macrophages to mycobacteria.

Authors:  Joseph P Lopez; David J Vigerust; Virginia L Shepherd
Journal:  Respir Res       Date:  2009-07-01

8.  Effect of nebulized bovine surfactant for experimental otitis media with effusion.

Authors:  Chul Ho Jang; Yong Bum Cho; Seung Eun Oh; Jeong Uk Choi; Haekyun Park; Cheol Hee Choi
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

9.  Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses.

Authors:  K L Hartshorn; E C Crouch; M R White; P Eggleton; A I Tauber; D Chang; K Sastry
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

10.  Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses.

Authors:  Stephen B Gordon; Rose Malamba; Neema Mthunthama; Elizabeth R Jarman; Kondwani Jambo; Khuzwayo Jere; Eduard E Zijlstra; Malcolm E Molyneux; John Dennis; Neil French
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.